,i #aahth ,,congress #ast ,session ,h4 ,r4 #ajib ,,in ,,the ,,house ,,of ,,representatives ,february #ag1 #bjbc,ms4 ,matsui 7for herself and ,mr4 ,wenstrup7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs4 #a4 ,short title ,this ,act may be cited as the ,better ,empowerment ,now to ,enhance ,framework and ,improve ,treatments ,act of #bjbc or the ,,benefit ,act of #bjbc4 #b4 ,strengthening the use of patient-experience data within risk-benefit framework ,section #efi;,c of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#h;c7 is amended-- 7#a7 in subsection 7a77#a7-- 7,a7 in subparagraph 7,a71 by striking 2 and and inserting a semicolon2 7,b7 in subparagraph 7,b71 by striking the period and inserting 2 and2 and 7,c7 by adding at the end the following3 7,c7 as part of the risk-benefit assessment framework in the new drug approval process described in section #eje7;d71 considering patient experience data submitted by the medical product sponsor or another party4 2 and 7#b7 in subsection 7b77#a71 by inserting 1 including a description of how such data and information were considered in the risk-benefit assessment described in section #eje7;d7 before the period at the end4